What is the prevalence of Megalencephaly Capillary Malformation Polymicrogyria Syndrome (mcap)?

Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP) is an ultra-rare genetic overgrowth disorder with an estimated prevalence of fewer than 1 in 1,000,000 individuals worldwide. Because the condition is often misdiagnosed or under-recognized, the true number of people living with MCAP is likely higher than current clinical literature suggests.

How common is MCAP and what are the challenges in tracking it?

MCAP is classified as an ultra-rare condition, meaning it affects a very small percentage of the global population. Accurate epidemiological data remains elusive because Megalencephaly Capillary Malformation Polymicrogyria Syndrome presents with a highly variable spectrum of symptoms, leading to frequent misdiagnosis as other overgrowth syndromes. Currently, there is no reliable data on annual incidence rates, as many cases are sporadic mutations that occur post-conception.

What are the demographic patterns of MCAP?

Research indicates that Megalencephaly Capillary Malformation Polymicrogyria Syndrome does not show a strong preference for specific ethnic or geographic groups. Regarding gender distribution, the condition is identified in both males and females, though some literature suggests a slight female predominance in clinical reports. Key demographic facts include:

• Age of Onset: MCAP is congenital, with physical markers like macrocephaly and capillary malformations typically present at birth or in early infancy.


• Inheritance: Most cases of Megalencephaly Capillary Malformation Polymicrogyria Syndrome arise from mosaic post-zygotic mutations in the PIK3CA gene, meaning it is generally not inherited from parents.


• Community Insight: At DiseaseMaps.org, we currently support 23 individuals living with Megalencephaly Capillary Malformation Polymicrogyria Syndrome, providing a vital, real-world perspective that complements limited clinical data.

Why is accurate diagnosis difficult?

The rarity of Megalencephaly Capillary Malformation Polymicrogyria Syndrome makes it difficult for primary care physicians to identify the condition immediately. Diagnostic delays often occur because the physical signs, such as skin capillary malformations and brain overgrowth, may be subtle or mistaken for more common pediatric developmental issues. Specialized genetic testing to identify PIK3CA mutations is often required to confirm a diagnosis of Megalencephaly Capillary Malformation Polymicrogyria Syndrome.

Next steps

• Consult with a clinical geneticist to discuss targeted genetic testing for PIK3CA-related overgrowth spectra.


• Connect with the 23 community members at DiseaseMaps.org to share experiences and find peer support.


• Monitor the NIH GARD website for updates on clinical trials and research advancements regarding this condition.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): MCAP Syndrome overview.


• Orphanet: Rare disease database entry for Megalencephaly-capillary malformation syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #602501 for MCAP.